Notably, in contrast to previous reports on palliative care in children, in which most children died at home, most of the children who died during the study period died in the hospital or in the intensive care unit. In fact, some of the children died while receiving interventions, such as the placement of a percutaneous endoscopic gastrostomy tube.
A majority of the data available on children with life-limiting conditions (LLCs) who need palliative care focus on children with cancer. However, the majority of children with LLCs have other diagnoses, such as genetic conditions or metabolic diseases, and data on this population are few.
A study newly published in the Orphanet Journal of Rare Diseases sought to determine how many children are affected by incurable metabolic diseases and to analyze palliative care in this group. The study was conducted in a single center in Germany, where all children with LLCs are guaranteed palliative care.
The researchers found that between 2013 and 2016, of the 198 children receiving palliative care in the center, 29 (14.6%) had metabolic diseases (including lysosomal storage diseases, fatty acid disorders, mitochondrial diseases, and methionine metabolism disorders, among others).
The symptom burden for these patients was high, and it remained high throughout care. For the 24 children with metabolic diseases for whom the researchers were able to analyze data on the first 30 days of care, gastrointestinal, respiratory, and neurologic symptoms were the most common. In total, 12 of these patients had unplanned hospital readmissions at least once during care. Comparing children referred to palliative care at less than 1 year of age with those referred after age 10, younger children had a shorter period of care and died at a younger age.
The researchers report that, during advance planning, it was difficult for patients’ parents to limit life-extending care; more than one-third of all parents (37.8%) opted for the full range of life-extending measures for their children during initial discussions. Only 4 parents requested a do-not-resuscitate order, and 14 requested more conservative life-support measures, such as ventilation support or antibiotics.
Notably, in contrast to previous reports on palliative care in children, in which most children died at home, most of the children who died during the study period died in the hospital or in the intensive care unit. In fact, some of the children died while receiving interventions, such as the placement of a percutaneous endoscopic gastrostomy tube.
Therefore, the authors conclude, discussions of life-extending measures and the preferred place of death are of particular importance in this patient population, and these discussions should be given greater attention in the advance care planning period.
Reference
Hoell JI, Warfsmann J, Distelmaier F, Borkhardt A, Janßen G, Kuhlen M. Challenges of palliative care in children with inborn metabolic diseases [published online July 9, 2018.] Orphanet J Rare Dis. doi: 10.1186/s13023-018-0868-5.
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
January 23rd 2024Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Interventions Needed to Increase DMT Uptake in Sickle Cell Disease
December 26th 2023A recent study found that uptake of disease-modifying therapies (DMTs) has been low among patients with sickle cell disease, suggesting that more interventions that consider individual patient characteristics are needed to improve adoption.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More